By The SATimes News Service
New Delhi: Russia’s sovereign wealth fund has agreed a deal to sell 100 million doses of its Covid-19 vaccine, Sputnik-V, to India. The media also reported that Indian pharmaceutical giant, Dr Reddy’s Laboratories based in Hyderabad will be responsible for marketing and distributing the vaccine in the country.
Clinical trials of the Russian vaccine in India are expected to follow and to be held jointly with Dr Reddy’s. Both the trials and supply deal depend on domestic regulatory approval.
Russia has billed Sputnik-V as the first vaccine against coronavirus to be registered in the world. Large-scale trials, known as Phase III, involving at least 40,000 people, were launched in Russia on Aug. 26. New reports to come out of clinical studies have found that 1 in 7 people suffered from side-effects post being inoculated by the Russian vaccine. Russia’s health minister, Mikhail Murashko, in a statement said that nearly 14% of patients who have been administered the vaccine reported suffering from side-effects.
India is the second-worst affected nation struck by the COVID-19 pandemic. The total number of cases stood at 5.02 million mark as of September 16.